In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paragon Bioservices Inc.

Division of Catalent Inc.
paragonbioservices.com

Latest From Paragon Bioservices Inc.

Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell

Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.

 

M & A Regenerative Medicine

Gene Therapy Manufacturers Are Highly Sought Acquisition Targets

Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.

BioPharmaceutical Market Intelligence

Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

Deals Business Strategies

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Catalent Inc.
  • Senior Management
  • Pete Buzy, Pres. & CEO
    Gerard Fleury, CFO
    Philip W Wills, PhD, Chief Commercial Officer
    William D Thomas, Jr., PhD, CSO
    Thomas Vancott, PhD, Chief Tech. & Strategy Officer
  • Contact Info
  • Paragon Bioservices Inc.
    Phone: (800) 545-6569
    801 West Baltimore St.
    Ste. 302
    Baltimore, MD 21201
    USA
UsernamePublicRestriction

Register